Topical spironolactone, a skin-applied cream, gel, or solution designed to block androgen signals in skin, remains investigational for adult persistent acne. The 2026 Clinical, Cosmetic and Investigational Dermatology review rates its certainty as low and calls it promising but limited.
The review pooled only five clinical trials with 195 total patients, according to Dove Medical Press in the full 2026 review. The same review frames oral use for moderate-to-severe adult female acne and topical use as experimental. That gap matters when choosing a treatment with a dermatologist.
Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.
Table of Contents
- What did the 2026 review decide?
- Why are the topical trials too small to trust?
- How does oral spironolactone evidence compare?
- What should adults with persistent acne do?
What did the 2026 review decide?
The review treats topical spironolactone as investigational rather than routine care. It finds early signals of benefit but judges the support as limited and partly indirect.
No trial directly compared topical versus oral spironolactone. No topical formulation is commercially established, and the review found no regulatory-grade topical program.
Why are the topical trials too small to trust?
No topical trial enrolled more than about 80 patients, and treatment periods were short. Small, brief trials miss slow acne change and rare skin reactions.
The studies also differed in key ways. They tested heterogeneous 2-5 percent creams, gels, or solutions and used nonstandard lesion counts and severity scales. Some enrolled healthy male volunteers or mixed-sex groups rather than only adult women with persistent acne, according to the earlier systematic review summarized in the Journal of Dermatology analysis.
How does oral spironolactone evidence compare?
Oral spironolactone has larger, longer tests in the target group. The SAFA pragmatic, multicentre, phase 3 double-blind trial randomized 410 women with persistent facial acne to spironolactone plus topical care versus placebo plus topical care, as described by the NIHR Journals Library in the SAFA trial summary.
A 2025 meta-analysis of seven randomized placebo-controlled trials with 643 participants found lower acne severity scores with spironolactone at four to 12 weeks. Total-lesion, comedone, and papule effects were inconsistent across trials. That pattern supports oral use in selected adults while leaving dose, duration, and long-term safety to clinical judgment.
What should adults with persistent acne do?
Do not treat compounded topical spironolactone as equal to an approved topical anti-androgen. Clascoterone 1 percent cream is the FDA-approved topical androgen-receptor inhibitor supported by phase 3 trials, while topical spironolactone remains off-label or compounded, as discussed in the JCAD narrative review. Ask a dermatologist for a plan based on severity, prior topicals, pregnancy plans, and potassium or kidney risks with oral therapy.
- List current prescription topicals, benzoyl peroxide, and retinoid use
- Note acne location, cycle flares, and prior hormonal treatment
- Ask whether clascoterone, oral spironolactone, or another guideline-based option fits
- Avoid ordering compounded spironolactone lotion online without a prescription and follow-up
You Might Also Like
- Topical Clascoterone Evidence Revisited in 2026: Study Design and Evidence Limits for Adults With Persistent Acne
- Topical Clascoterone Evidence Revisited in 2026: What the Findings Mean for Adults With Persistent Acne
- The 2026 Review of Topical Antibiotic Monotherapy for Acne: Questions Adults With Persistent Acne Can Ask a Dermatologist